Published in TB and Outbreaks Week, February 3rd, 2004
Researchers in Israel conducted a study "to assess the efficacy of amphotericin B (AMB), AMB-intralipid admixture (AMB-IL) or nystatin-IL formulation (Ny-IL) in combination with granulocyte colony stimulating factor (G-CSF) in treatment of experimental murine aspergillosis."
"ICR mice were immunosuppressed by cyclophosphamide and three days later inoculated intravenously (i.v.) with Aspergillus fumigatus," explained E. Sionov and coauthors at Tel Aviv University. "Treatment was initiated 2 hours later and administered for 5 consecutive days (polyenes, i.v.;...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.